

Certificate of Analysis

Abl (H396P), active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-750, 14-750-K, 14-750M

Parent Lot # D7BN009U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged recombinant human Abl, residues 27–end containing the H396P mutation. Expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose.

The Abl tyrosine kinase inhibitor STI571 (Gleevec™) is an effective therapy for stable-phase chronic myeloid leukaemia patients. Many patients responding to STI571 later relapse, due to a reactivation of Bcr-Abl activity. In certain cases this appears to correlate with the presence of the H396P mutation, which confers resistance to drug binding due to steric interference. (Corbin AS. *et al*, Blood, (2002); **101:4611-4614** and La Rosee P. *et al*, Cancer Research; **62:7149-7153**).

Purity 23% by SDS-PAGE and Coomassie staining. MW = 121.4kDa.

Specific Activity (Parent lot# D7BN009U): 1790U/mg, where one unit of Abl (H396P), active activity is defined as 1nmol phosphate incorporated into 50µM Abltide (EAIYAAPFAK) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 1.92mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1mM EGTA, 0.1% 2-mercaptoethanol, 0.03% Brij-35. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 2.1–5.8ng of this lot of enzyme phosphorylated 50µM Abltide in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as Abl (H396P) with the translated sequence listed on page three.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of Abl (H396P), active.

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Abltide (EAIYAAPFAKKK):** Use at a final assay concentration of 50 μ M. Prepare a 500 μ M stock and add 2.5 μ l of stock per assay point.
3. **Abl (H396P), active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 2.1–5.8ng per assay point.
4. **[γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5 μ l of 5 x reaction buffer per assay to wells.
2. Add 2.5 μ l of **Abltide**.
3. Add **2.5 μ l (2.1–5.8ng) Abl (H396P), active**.
4. Add 5 μ l of dH₂O.
5. Add 10 μ l of diluted [γ -³³P] ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
8. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

Abl (H396P) Sequence Information

<u>Protein</u>	Human Abl (27–end, H396P)
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	E10 of the recombinant protein is equivalent to E27 of human Abl
<u>Accession number</u>	GenBank U07563

Recombinant Abl (H396P) amino acid sequence:

```

1 MHHHHHEFE ALQRPVASDF EPQGLSEEAR WNSKENLLAG PSENDPNLFV ALYDFVASGD
61 NTLSTITKGEK LRVLGYNHNG EWCEAQTKNG QGWVPSNYIT PVNSLEKHSW YHGPVSRNAA
121 EYLLSSGING SFLVRESESS PGQRSISLRY EGRVYHYRIN TASDGKLYVS SESRFNTLAE
181 LVHHHSTVAD GLITTLHYPA PKRNKPTVYG VSPNYDKWEM ERTDITMKHK LGGGQYGEVY
241 EGVWKKYSLT VAVKTLKEDT MEVEEFLKEA AVMKEIKHPN LVQLLGVCTR EPPFYIITEF
301 MTYGNLLDYL RECNRQEVNA VLLYMATQI SSAMEYLEKK NFIHRDLAAR NCLVGENHLV
361 KVADFGLSRL MTGDTYTAPA GAKFPIKWTA PESLAYNKFS IKSDVWAFGV LLWEIATYGM
421 SPYPGIDLSQ VYELLEKDYR MERPEGCPEK VYELMRACWQ WNPSDRPSFA EIHQAFETMF
481 QESSISDEVE KELGKQGV RG AVSTLLQAPE LPTKTRTSRR AAEHRDITDV PEMPHSKGQG
541 ESDPLDHEPA VSPLLPRKER GPPEGGLNED ERLLPKDKKT NLFSAI LKKK KKTAPT PPKR
601 SSSFREMDGQ PERRGAGEEE GRDISNGALA FTPLDTADPA KSPKPSNGAG VPNGALRESG
661 GSGFRSPHLW KKSSTLTSSR LATGEEEGGG SSKRFLRSC SASCVPHGAK DTEWRSVTLP
721 RDLQSTGRQF DSSTFGGHKS EKPALPRKRA GENRSDQVTR GTVTPPPRLV KKNEEADEV
781 FKDIMESSPG SSPNLT PKP LRRQVT VAPA SGLPHKEEAG KGSALGTPAA AEPVTPSKA
841 GSGAPGGTSK GPAEESRVRH HKHSSSESPGR DKGKLSRLKP APPPPPAASA GKAGGKPSQS
901 PSQEAAGEAV LGAKTKATSL VDAVNSDAAK PSQPGEGLKK PVLPATPKPQ SAKPSGTPIS
961 PAPVPSTLPS ASSALAGDQP SSTAFIPLIS TRVSLRKT RQ PPERIASGAI TKGVVLDSTE
1021 ALCLAISRNS EQMASHSAVL EAGKNLYTFC VSYVDSIQQM RNKFAFREAI NKLENNLREL
1081 QICPATAGSG PAATQDFSKL LSSVKEISDI VQR

```

Recombinant Abl (H396P) nucleotide sequence:

```

1 atgcatcatc accatcacca tgaattcgaa gcccttcagc ggccagtagc atctgacttt
61 gagcctcagg gtctgagtga agccgctcgt tggaactcca aggaaaacct tctcgctgga
121 cccagtgaaa atgaccccaa cttttcgtt gcactgtatg attttgtggc cagtggagat
181 aacactctaa gcataactaa aggtgaaaag ctccgggtct taggctataa tcacaatggg
241 gaatggtgtg aagcccaaac caaaaatggc caaggctggg tccaagcaa ctacatcacg
301 ccagtcaaca gtctggagaa acactcctgg taccatgggc ctgtgtcccg caatgccgct
361 gagtatctgc tgagcagcgg gatcaatggc agcttcttgg tgcgtgagag tgagagcagt
421 cctggccaga ggtccatctc gctgagatac gaaggagggt tgtaccatta caggatcaac
481 actgcttctg atggcaagct ctacgtctcc tccgagagcc gcttcaacac cctggccgag
541 ttggttcatc atcattcaac ggtggccgac gggctcatca ccacgctcca ttatccagcc
601 ccaaagcgca acaagcccac tgtctatggt gtgtcccca actacgaca gtgggagatg
661 gaagcagcgg acatcaccat gaagcacaag ctgggcgggg gccagtacgg ggaggtgtac
721 gagggcgtgt ggaagaaata cagcctgacg gtggccgtga agaccttga ggaggacacc
781 atggaggtgg aagagttctt gaaagaagct gcagtcatga aagagatcaa acaccctaac
841 ctggtgcagc tccttggggc ctgcaccgg gagccccgt tctatatcat cactgagttc
901 atgacctacg ggaacctcct ggactacctg agggagtgca accggcagga ggtgaacgcc
961 gtggtgctgc tgtacatggc cactcagatc tcgtcagcca tggagtacct ggagaagaaa
1021 aacttcatcc acagagatct tgctgccga aactgcctgg taggggagaa ccacttgggtg
1081 aaggtagctg attttggcct gagcaggttg atgacagggg acacctacac agcccctgct
1141 ggagccaagt tccccatcaa atggactgca cccgagagcc tggcctacaa caagttctcc
1201 atcaagtccg acgtctgggc atttggagta ttgctttggg aaattgctac ctatggcatg

```

Certificate of Analysis

```

1261 tcccccttacc cgggaattga cctgtcccag gtgtatgagc tgctagagaa ggactaccgc
1321 atggagcgcc cagaaggctg cccagagaag gtctatgaac tcatgcgagc atgttggcag
1381 tggaatccct ctgaccggcc ctcctttgct gaaatccacc aagcctttga aacaatgttc
1441 caggaatcca gtatctcaga cgaagtggaa aaggagctgg ggaacaagg cgtccgtggg
1501 gctgtgagta ccttgctgca ggccccagag ctgcccacca agacgaggac ctccaggaga
1561 gctgcagagc acagagacac cactgacgtg cctgagatgc ctactccaa gggccaggga
1621 gagagcgatc ctctggacca tgagcctgcc gtgtctccat tgctccctcg aaaagagcga
1681 ggtcccccgaggggcgcct gaatgaagat gagcgccttc tccccaaaga caaaaagacc
1741 aacttgttca ggccttgat caagaagaag aagaagacag cccaacccc tcccaaaccg
1801 agcagctcct tccgggagat ggacggccag ccggagcgca gggggccgg cgaggaagag
1861 ggccgagaca tcagcaacgg ggactggct ttcaccctc tggacacagc tgaccagcc
1921 aagtccccaa agcccagcaa tggggctggg gtcccaatg gagcctccg ggagtccggg
1981 ggctcaggct ccacgtctcc ccactgtgg aagaagtcca gcacgctgac gcagagccg
2041 ctagccaccg gcgaggagga gggcgtggc agctccagca agcgcttct cgctcttgc
2101 tccgctcctc gcttccccca tggggccaag gacacggagt ggaggtcagt cacgctgcct
2161 cgggacttgc agtccacggg aagacagtt gactcgtcca catttggagg gcacaaaagt
2221 gagaagccgg ctctgcctcg gaagaggga ggggagaaca ggtctgacca ggtgaccgga
2281 ggcacagtaa cgctcccc caggctggtg aaaaagaatg aggaagctgc tgatgaggtc
2341 ttcaaagaca tcatggagtc cagcccggc tccagcccgc ccaacctgac tccaaaacc
2401 ctccggcggc aggtcacctg ggcccctgcc tcgggctcc cccacaagga agaagctgga
2461 aaggcgagtg ccttagggac ccctgctgca gctgagccag tgacccccac cagcaaagca
2521 ggctcaggtg caccaggggg caccagcaag ggccccgccc aggagtccag agtgaggagg
2581 cacaagcact cctctgagtc gccagggagg gacaagggga aattgtccag gctcaaacct
2641 gccccgccc ccccaccagc agcctctgca ggggaaggctg gaggaaagcc ctgcagagc
2701 ccgagccagg agggggcgg ggaggcagtc ctgggcgcaa agacaaaagc cacgagtctg
2761 gttgatgctg tgaacagtga cgctgccaag cccagccagc cgggagaggg cctcaaaaag
2821 cccgtgctcc cggccactcc aaagccacag tccgccaagc cgtcggggac cccatcagc
2881 ccagccccg ttcctccac gttgcatca gcatcctcgg ccctggcagg ggaccagccg
2941 tcttccaccg ccttcatccc tctatatca acccgagtgt ctcttcggaa aaccgcccag
3001 cctccagagc ggatcgccag cggcgccatc accaaggcg tggtcctgga cagcaccgag
3061 gcgctgtgcc tcgccatctc taggaactcc gagcagatgg ccagccacag cgagtgctg
3121 gaggccggca aaaacctcta cacgttctgc gtgagctatg tggattccat ccagcaaatg
3181 aggaacaagt ttgccttccg agaggccatc aacaaactgg agaataatct cggggagctt
3241 cagatctgcc cggcgacagc aggcagtggg ccagcgcca ctcaggactt cagcaagctc
3301 ctcagttcgg tgaaggaaat cagtgatata gtgcagaggt ag

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services